NCT01201902View on ClinicalTrials.gov

A Study to Evaluate the Safety and Immunogenicity of an Inactivated Split-virion Influenza A(H1N1) Vaccine

PHASE3CompletedINTERVENTIONAL
Enrollment

592

Participants

Timeline

Start Date

October 31, 2009

Primary Completion Date

December 31, 2009

Study Completion Date

July 31, 2010

Conditions
Influenza Infection
Interventions
BIOLOGICAL

Adjuvanted influenza A(H1N1) vaccine

0.25ml, Intramuscular on Day 0 and 21

BIOLOGICAL

Adjuvanted influenza A(H1N1) vaccine

0.5ml, Intramuscular on Day 0 and 21

BIOLOGICAL

un-adjuvanted influenza A(H1N1) vaccine

0.5ml, Intramuscular on Day 0 and 21

BIOLOGICAL

Adjuvanted influenza A(H1N1) vaccine

0.25ml, Intramuscular on Day 0 and 21

BIOLOGICAL

Adjuvanted influenza A(H1N1) vaccine

0.5ml, Intramuscular on Day 0 and 21

Sponsors
All Listed Sponsors
lead

Green Cross Corporation

INDUSTRY